Does Emend Help with Delayed Nausea After Chemo?
Yes, Emend (fosaprepitant dimeglucil or aprepitant) effectively reduces delayed nausea and vomiting after chemotherapy, especially for highly emetogenic regimens like cisplatin-based treatments. Clinical trials show it cuts the risk of delayed CINV (chemotherapy-induced nausea and vomiting) by 70-80% when combined with other antiemetics like dexamethasone and a 5-HT3 antagonist.[1][2]
How Does Emend Work for Delayed Nausea?
Emend targets NK1 receptors in the brain, blocking substance P—a key trigger for delayed nausea that starts 24+ hours post-chemo. Unlike 5-HT3 blockers (e.g., ondansetron) that mainly handle acute nausea, Emend's 3-5 day coverage addresses the delayed phase, where nausea often peaks days 2-5.[1][3]
What Do Studies Show on Effectiveness?
In pivotal trials for aprepitant (Emend's oral form), adding it to standard therapy dropped delayed vomiting rates from 23% to 2% and nausea from 42% to 19% in patients on highly emetogenic chemo.[2] A 2023 meta-analysis confirmed similar results for fosaprepitant IV, with number-needed-to-treat around 5-7 for preventing delayed CINV.[4] It works less well for moderately emetogenic chemo alone.
Who Gets Emend and When?
Guidelines from ASCO, NCCN, and MASCC recommend Emend for patients at high risk of delayed CINV (e.g., cisplatin >50 mg/m², carboplatin AUC ≥4.5, or anthracyclines). It's given as a single IV dose on day 1 (115 mg fosaprepitant) or 125 mg oral aprepitant, followed by 80 mg oral doses on days 2-3.[3][5] Not first-line for low-risk chemo.
Common Side Effects Patients Report
Fatigue (15-20%), diarrhea (10%), hiccups (5-10%), and constipation occur most often. Rare risks include liver enzyme elevation or allergic reactions. It's metabolized by CYP3A4, so avoid with strong inhibitors like ketoconazole.[1][6] Patients note less "hangover nausea" compared to steroids alone.
How Does It Compare to Alternatives?
| Drug/Combo | Delayed Nausea Control | Dosing | Cost Edge |
|------------|-------------------------|--------|-----------|
| Emend + dex + 5-HT3 | Best for high-risk (75-85% complete response) | 3 days | Higher upfront |
| Rolapitant (Varubi) | Similar efficacy, single dose | Day 1 only | Comparable |
| Olanzapine + standard | Good add-on, cheaper | Daily | Off-label, sedating |
| Dex + 5-HT3 alone | 50-60% response | Shorter | Lowest cost |
Emend outperforms double therapy but costs more; generics help since 2020.[2][7]
When Does the Patent Expire?
Emend's key patents (aprepitant composition) expired in 2026 in the US, with generics like MSN's approved in 2023 via FDA tentative ANDA. Check DrugPatentWatch.com for litigation updates on remaining pediatric or formulation patents.[8]
Sources
[1]: Emend Prescribing Information (Merck)
[2]: NEJM 2003; Aprepitant Trials
[3]: MASCC/ESMO Antiemetic Guidelines 2023
[4]: Support Care Cancer 2023 Meta-Analysis
[5]: NCCN Antiemesis Guidelines v2.2024
[6]: FDA Adverse Events Database
[7]: Varubi Prescaking Info (Tesaro)
[8]: DrugPatentWatch.com - Emend Patents